Daniel Rabinowitz, the Chief Legal Officer of Natera, Inc., executed a sale of 341 shares of the company’s common stock on November 2, 2026. This transaction is significant as it underscores the ongoing stock activity within Natera and the medical laboratory services industry.

According to the recent SEC filing, the shares were sold to satisfy tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). The sale was conducted under a written instruction intended to comply with the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Background

Natera, Inc. is a company focused on providing medical laboratory services, specifically in genetic testing and diagnostics. The company is incorporated in Delaware and has its business address in Austin, Texas. Natera operates under the SIC classification for medical laboratories, which highlights its role in the healthcare sector.

What the Filing Says

The filing reveals that Rabinowitz sold 7 shares at a price of $388.20 each and 334 shares at $400.29 each. Following these transactions, he retained a total of 168,214 shares of Natera’s common stock.

Impact

This sale may affect Rabinowitz's ownership stake in Natera, though he remains a significant shareholder with over 168,000 shares post-transaction. The filing does not indicate any immediate impact on the company’s operations or stock performance.

What's Next

The filing does not say what happens next.